Exodus Point Capital Management, LP Cel Sci Corp Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 19, 2022	SELL	$2.58 - $4.99 $25,944 - $50,179	-10,056 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$3.93 - $7.7 $119,456 - $234,049	-30,396 Reduced 75.14%	10,056 $40,000
Q4 2021 Feb 11, 2022	BUY	$7.1 - $12.82 $287,209 - $518,594	40,452 New	40,452 $287,000
Q3 2021 Nov 15, 2021	SELL	$7.64 - $12.49 $269,722 - $440,946	-35,304 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$8.68 - $27.49 $306,438 - $970,506	35,304 New	35,304 $306,000
Q4 2020 Feb 16, 2021	SELL	$11.05 - $16.62 $169,882 - $255,515	-15,374 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$11.69 - $14.54 $179,722 - $223,537	15,374 New	15,374 $196,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $30.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.